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Abstract
Health-care professionals who prescribe medicines have the professional duty to choose medicines that are in the best interest of
their individual patient, irrespective if that patient is an adult or a child. However, the availability of medicines with an appropriate
label for pediatric use is lagging behind those for adults, and even available pediatric drugs are sometimes not suitable to
administer to children. Consequently, health-care professionals often have no other option than to prescribe off-label medicines
to children. An important reason for use of off-label medicines is to improve access to (innovative) treatments or to address
medical needs and preferences of patients, especially when no other options are available. However, off-label use of medicines is
in general not supported by the same level of evidence as medicines licensed for pediatric use. This may result in increased
uncertainty on efficacy as well as the risk for toxicity and other side effects. In addition, liability may also be of concern,
counterbalanced by professional guidelines.
Conclusion: The purpose of this joint EAP/ESDPPP policy statement is to offer guidance for HCPs on when and how to
prescribe off-label medicines to children and to provide recommendations for future European policy.
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Introduction
Health-care professionals (HCPs), in close collaboration with
pharmacists, who prescribe medicines, have the professional
duty to choose medicines that are in the best interest of their
individual patient. However, the availability of medicines with
an appropriate label for pediatric use is lagging behind those
for adults, and available pediatric drugs are often not suitable
to administer to children [1]. As a result, HCPs often have no
other option than to prescribe medicines to children outside
the approved conditions for age, therapeutic indication, dose
recommendation, formulation, and/or route of administration
(i.e., off-label use [2]) or to prescribe a drug which has not
received a license for use in adults or children (i.e., unlicensed
medicines use [2]). The practice of off-label prescribing of
medicines to children is substantial, both in hospital care and
primary health care [3]. A recent report on the setting in the
European Union indicates that off-label use of medicines in
children is still widespread. Off-label use varies among
European countries, with 13–69% of prescriptions being off-
label in the hospital setting and 2–100% in primary care [4].
European guidelines on off-label use of medicines in chil-
dren could greatly benefit children, parents, and their HCPs.
Therefore, the purpose of this joint policy statement – en-
dorsed by both councils of the European Academy of
Pediatrics and the European Society for Developmental
Perinatal and Pediatric Pharmacology – is to offer guidance
for these HCPs and to provide recommendations for any fu-
ture European policy.
European views on off-label use of medicines
According to recent survey findings among European stake-
holders, off-label use of medicines is perceived to have both
advantages and disadvantages. An important advantage is the
accelerated access of patients to (innovative) treatments and
the appropriate treatment of medical conditions in patients,
when no other options are suitable. On the other hand, the
issue of liability in case of negative consequences of off-
label use is a widely recognized concern as a formal assess-
ment of safety and efficacy by the relevant authorities has not
been performed. Furthermore, friction between national
authorities and the pharmaceutical industry may occur if eco-
nomic reasons are prevailing [4].
The development of medicines for children is compli-
cated by a small and heterogeneous market and methodo-
logical and ethical requirements specific for pediatric trials
[5]. As a result, many medicines are not labeled for use in
children. In order to improve this situation, there have been
a number of initiatives, including the European Pediatric
Regulation. It has been estimated that more than 50% of
medicines used in children have not been tested for the
specific age group [6]. In addition, medicines labeled for
use in children may underperform with respect to their
ability to provide the recommended dose, the suitability
of the dosage form, and the presence of potential harmful
excipients [7]. For example, the availability of melting or
chewable tablets, more likely taken by younger children,
appears to be limited [1]. Typical therapeutic areas of off-
label use in children include – but are not limited to –
infectious diseases, cardiology, dermatology, pain treat-
ment, alimentary tract and metabolism, the respiratory sys-
tem, and the central nervous system [4]. The highest fre-
quency of off-label use of medicines is seen in patients
treated in the NICU, PICU, and children with oncologic
diseases.
By using off-label medicines, prescribers, children, and
their families have more treatment options to discuss in order
to provide a treatment that one finds most appropriate for the
needs of the individual patient. In addition, based on the
newest available scientific evidence, (innovative) medicines
(type of drug, dose, and/or indication) can be prescribed to
patients at an earlier stage before the required regulatory ap-
proval has been finalized or adopted [4]. However, as off-label
use of medicines are in general not supported by the same level
of preclinical and clinical evidence as medicines licensed for
pediatric use, this may result in increased uncertainty on effi-
cacy as well as the risk for toxicity [7], and prescribers and
patients have less information at their disposal to decide to
choose (prescriber) or accept (patient) the off-label treatment
[4]. Finally, the issue of liability may also be a concern, though
often counterbalanced by available professional guidelines [4].
Off-label prescribing is not regulated by European law [9].
European legislation only regulates the marketing of medi-
cines and not the waymedicines are ultimately used in clinical
practice, which is a national competence or is captured in
paralegal statements or guidelines on good practice.
Prescribing on-label or off-label medicines is a decision taken
within the relationship between a patient and the prescriber.
The professional setting (both legal and paralegal) does not
limit the right of prescribers to prescribe medicines to “on-
label” prescriptions only, as this would in many cases lead to
a conflict of professional duties. Therefore, in practice, at the
national level, off-label use of medicines is often ethically and
legally “accepted” under restrictions.
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Several European countries have adopted special statutory
regulations for off-label use of medicines and have good prac-
tice or professional guidelines for use, including reimburse-
ment decisions (Tables 1, 2, 3). These regulations or policy
tools aim for improvement of knowledge regarding efficacy
and safety of off-label use. This regulation to encourage phar-
maceuticals to file a license extension and/or to create the
opportunity to apply research results immediately in a licensed
setting is counterbalanced by the uncertainties related to reim-
bursement practices. In countries where no policy tools are in
place, the predominant argument is that off-label use of med-
icines is an issue that should be dealt with in the context of the
relationship between prescriber and patient rather than at level
of the regulatory or health-care system [4].
European policy statement on prescribing
off-label or unlicensed drugs to children
Off-label use of medicines is subject to several conditions.
According to the Court of Justice of the European Union
(CJEU), off-label use should remain exceptional in order to
preserve the practical effect of the licensing procedure for
medicines. Prescribing off-label medicine (1) should be limit-
ed to individual situations justified by medical considerations,
(2) should be under the responsibility of the prescriber, (3)
presupposes that the medicine is necessary to address the
needs of the patient, (4) should follow a full assessment and
examination of the patient, and (5) should be decided on the
basis of purely therapeutic considerations [4].
Table 1 National temporary recommendations for off-label use of medicinesa
Country When off-label prescribing? How?
Belgium The evaluation of the individual practitioner’s choice
implies an evaluation of possible alternatives, including
alternative treatments, alternative medicinal treatments,
and alternatives to a treatment, but in essence, there is
“therapeutic freedom”
After informed consent of the parents and patient and after
clinical examination
France
No. 2011–2012 act (RTU)
If prescriber deems it necessary for patient, given scientific
knowledge and absence of available alternative treatment
Or
If medicine is part of “Recommendations for use (RTU)”
scheme. An RTU for off-label use can be issued by the
French Agency if certain criteria are met
Prescriber must justify choice
Informed consent is required
If medication is part of RTU: prescriber should mention this
on prescription so that pharmacists can control
prescription in this context. The marketing authorization
holder should set up patient follow-up
RTU medicines are reimbursed by the national health
insurance
Italy
National Law n. 94/98 (Di
Bella Law), 648/96
National Law
If indication relates to therapeutic area with unmet medical
need, companies do not want to perform clinical trials for
given indication
Off-label use requires support of phase II completed study
Informed consent is required;
Reimbursed if application of law 648/96
Spain
National Royal Decree No.
1015/2009
Off-label use has to be exceptional and only limited to those
situations in which no approved alternative exists, with
respect to any restriction of the conditions for prescribing
and dispensing established in the authorization and the
therapeutic protocol of the center
Prescriber has to justify need in the clinical history
Informed consent is required
Prescriber must notify adverse events
Prescriber must comply with established recommendations
and therapeutic protocols
Switzerland
Federal law on medicinal
products and medical
devices, Art 9, Art 26
If it is proven that there is no authorized or available
alternative medicine that is applicable and equivalent
Hungary
Art 25 of Act XCV (2005),
subsection 6
(1) If treatment with licensed medicine is not possible or
unsuccessful
Or
(2) Access to licensed medicine is inhibited to an extent that
would likely delay treatment
Prescriber must ensure that:
Based on experimental evidence, medicine offers potential
of successful treatment or improve/stabilize patient
condition; medicine is licensed for distribution in
Hungary or another country; prescriber is specialist in
specific therapeutic area; prescriber’s request for use of
this medicine in specific patient has been granted by
government body for pharmaceuticals.
Risk/benefit balance of off-label medicine is better than that
of the licensed medicine; based on experimental
evidence, medicine offers potential of successful
treatment or improve/stabilize patient condition; the
SmPC of licensed medicine does not contain
contra-indication regarding requested unlicensed
indication
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HCPs who prescribe off-label medicines to children should
comply with ethical and professional standards. Divergence in
drug and social laws and institutional and professional rules
across Europe may complicate a uniform approach to pre-
scribing off-label medicines in children. Nevertheless, the
European Academy of Pediatrics and the European Society
for Developmental Perinatal and Pediatric Pharmacology
strongly recommend that the following conditions are consid-
ered when prescribing off-label medicines to neonates, in-
fants, children, or adolescents. We hereby suggest that this
may serve as a checklist for good practice.
Condition #1 All other options, including the use of medi-
cines approved by the regulatory authorities, are unavail-
able, not tolerated, less optimal, too expensive, not reim-
bursable by insurance companies, or containing potential-
ly harmful excipients.
Off-label use is not the same as off-knowledge use.
Condition #2 The prescriber is competent to prescribe off-
label medicines in children.
An off-label medicine can only be prescribed by someone
who has prescribing skills (rational drug therapy) and is
knowledgeable about off-label use of medicines in children
[10]. As children differ from adults with regard to disease
etiology, pharmacokinetic and pharmacodynamic factors,
and formulation acceptance, the prescriber should have spe-
cific knowledge and experience in the field of pediatrics.
Although most HCPs appear to be familiar with the practice
of off-label prescribing, most are not aware that the medicines
they prescribe are indeed off-label medicines [11]. As this may
have consequences for the monitoring of efficacy and adverse
events, it is crucial that the prescriber should be aware that he
or she is prescribing the medicine in an off-label manner.
Condition #3 Off-label prescription of the medicine is ap-
propriate tomeet the needs of the individual patient within
the available resources.
There are several situations in which it may be necessary to
prescribe a medicine in an off-label manner.
& There may be a medical need where there is no labeled
medicine available [4], or the labeled formulation or dos-
age is not age-appropriate. For example, most medicines
used in neonatology have not been tested for the appropri-
ate age and weight group, and most doses have been ex-
trapolated from adult and older children. Moreover, the
risk of administration errors can be reduced if age-
appropriate off-label drug formulations are prescribed. In
addition, off-label use is the rule and not the exception in
patients with rare diseases, like clobazam for epilepsy in
Dravet syndrome.
& Certain medicines may be licensed, available, and suitable
for use in children in one country, but not in another; for
example, midazolam oral suspension that is available in
Germany but not in Belgium, despite being licensed at the
European level.
Table 2 National measures to regulate reimbursement of off-label medicinesa
Country When off-label prescribing? How?
Belgium There is a Special Solidarity Fund for individual patients, but
the fund has limited resources. This is because the Belgian
reimbursement regulation is based on a positive list of
reimbursed products. Consequently, off label can potentially
qualify for reimbursement, not necessary linked to an
indication or age category. However, the request for addition
of a medicinal product to the positive list is the sole
responsibility of the marketing authorization holder
Hungary Case-by-case evaluation: decision to reimburse is taken based
upon circumstances (including existing alternatives and
reasons why these are not sufficient) and costs
Germany
Section 92 para (1)
Nr. 6 SGB V
The German Agency decides if off-label medicines are
reimbursed based on a scientific evaluation by its off-label
expert commissions.
Costs should be refunded also if there are only weak references
for efficacy, on condition that the patient suffers from a





Ministerial decree is required in special cases and according to
international bibliographic references
Off-label indications could be reimbursed if included in
therapeutic protocols approved by the Central Committee of
Health Council
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& The licensed medicine may (no longer) be appropriate
(has become obsolete), for example, due to the use of
harmful excipients (like ethanol or propylene glycol),
and an off-label medicine provides an appropriate alterna-
tive to use.
& An off-label medicine may address patient’s needs better
than the licensed medicine in cases when the licensed
medicine is minimally effective or ineffective or causes
unacceptable side effects, resulting in lower treatment ad-
herence [4].
& Off-label use may be part of the professional treatment
guideline [4], for example, in cases where product sum-
maries have not been updated (yet) despite available evi-
dence [12], such as aminoglycoside dosing in neonates
and infants. This type of off-label use allows physicians
to use existing medicines in an innovative way, when
Table 3 National guidance to professionals on off-label medicine use in childrena
Country When off-label prescribing? How?
Belgium When a suitable tested and approved alternative is available, prescribing
physicians’ liability may be at (increased) risk if safety issues arise. If an
adverse event arises through the use of that drug, the treating physician would
have the burden of proof to demonstrate that its use was performed as standard
of care. Key characteristics: usual or common practice, scientific basis, and
informed consent
Lithuania
Law of Pharmacy No. X-709
(2006)
Law of Patients’ rights,
safety and compensation
of harm No. I-1562 (1996)
Off-label use of licensed medicines is possible based on the decision of a council
or group of clinical pharmacologists if applicable. In the outpatient setting, it is
possible to prescribe off-label and extemporaneous medicines based on
experience and personal decision
Sweden
SFS 2010:659 and SFS
2014:821
If there is sufficient scientific evidence and clinical experience to prescribe
medicine, informed consent is required
UK
Good practice in prescribing
and managing medicines
and devices, 2013
Prescriber must be convinced that there is sufficient evidence or experience of
using medicine to demonstrate its safety and efficacy; NICE publishes evidence
summaries for off-label and unlicensed medicines
Prescriber has responsibility for prescribing the medicine; prescriber is responsible
for overseeing patient’s care, monitoring, and follow-up (or should ensure this is
done by another suitable physician); prescriber must have clear, accurate, and
legible record of prescribed medicines and reasons for prescribing medicine
off-label; informed consent is required.
Pediatric:
Royal College of Paediatrics and Child Health (Rev 2, 2013) [24]:
Where available, an appropriate licensed preparation should be prescribed and
supplied in preference to an unlicensed preparation.
In general, it is not necessary to take additional steps, beyond those taken when
prescribing licensed medicines, to obtain consent of parents, caregivers, and
child patients to prescribe or administer unlicensed medicines or licensed
medicines for unlicensed applications (off-label)b
The Netherlands
Art 68 of Medicines Act
If relevant professional body has
developed protocols or
professional standards with regard
to the specific off-label use
If protocols or standards are under
development, prescriber and
pharmacist are required to consult
each other.
Pediatric:
Dutch Pediatric Society (Rev 4, 2018) [26]: The Dutch Pediatric Society has
accepted the National Pediatric Formulary as expert guideline
Off-label use is considered appropriate if there is a medical need (no registered
medicine available or registered medicine is suboptimal for individual patient)
There should be a positive balance between expected efficacy and risks based on
available literature and assessed within multidisciplinary setting
Informed consent is required unless off-label use is documented in National
Pediatric Formulary or in professional guideline
The prescribing physician should inform parents/caregivers/child about the
benefits and risks of off-label or unlicensed use of medicines
Off-label treatment with medicines should be regularly and rigorously monitored
and adverse events should be reported nationally
Tables 1- 3a Based on information provided by EAP members and data included in [4, 27, 30]; b used definitions for off-label and unlicensed use may
vary across countries and publications2 . For example, in the UK, off-label use of drugs is referred to as “unlicensed use of licensed drugs”. No data:
countries not participating in EU study: e.g., Luxemburg, Norway, Switzerland, Iceland, Latvia, Poland, Romania, Croatia, Albania, Macedonia, Serbia,
Bosnia, and Herzegovina.
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evidence exists but formal licensing for children has not
taken place (yet) [4], as may be the case in pediatric on-
cology (e.g., rituximab for treatment of post-transplant
lymphoproliferative disease (PTLD)).
Condition #4 The off-label prescription should be rational
and clinically appropriate.
As with the use of licensed medications, the prescriber
must ensure the off-label prescription is appropriate, i.e., the
benefit/risk balance should be deemed positive for the indi-
vidual patient on the basis of the available evidence [4]. All
medicines have associated risks of adverse events. In the case
of on-label prescribing, the prescriber can rely on the medi-
cine’s evaluation by the competent authorities. In the case of
off-label prescribing, the prescriber has to weigh the benefit-
risk ratio. Off-label prescribing is considered appropriate if (1)
it is justified by best available evidence, preferably based on
professional guidelines supported by relevant societies (e.g.,
national pediatric and/or pharmacist societies); (2) it occurs
within the context of a formal research protocol; or (3) it
pertains to exceptional use, justified by individual clinical cir-
cumstances. If none of these justifications is present, its use is
generally not recommended (adapted from [13]).
If off-label prescribing is considered appropriate, the pre-
scriber will not automatically be liable for negative impacts on
the patient’s health, especially if the off-label use is mentioned
in a professional guideline or formulary.
Rational pharmacotherapy requires that patients receive
medicines appropriate to their clinical needs, in doses that
meet their own requirements, for an adequate period of time,
and at a reasonable cost to them and their community [14].
Formularies may be effective in improving rational pharma-
cotherapy in children [15]. In the UK and the Netherlands,
HCPs prescribing medicines to children are guided by infor-
mation in the British National Formulary for Children (BNF-
c) and the Dutch National Formulary for Children. In the
Netherlands, the development of this open-access formulary
has resulted in the revision of many consensus-based dose
recommendations and ensured uniformity in prescribing
habits in the Netherlands [16]. However, it is important to
emphasize that these formularies have still knowledge gaps,
like for optimal use of medicines in preterm neonates.
Condition #5 The patient and parents/caregivers should be
informed and involved.
When considering prescribing an off-label medicine, both
children and their parents/caregivers should have all the appro-
priate information available, if possible, regarding that medicine.
There is limited published literature about the views of pa-
tients, parents, and health-care professionals regarding in-
formed consent in off-label or unlicensed use of medicines in
children. In general, most children [17], parents [11, 18], and
citizens [19] feel that parents should be informed when a med-
icine is prescribed in an off-label or unlicensed manner, for
example, to create alertness to potential side effects [17]. In
addition, most older children feel that they also should be in-
formed [17]. The literature from health-care professionals is
more mixed: most health-care professionals in Northern
Ireland [20] felt that parents should be informed, whereas
hospital-based pediatricians in Scotland did not [21].
Knowledge about off-label or unlicensed use of medicines in
children is low among the general public [19] and in different
studies of parents of healthy and chronically ill children [11,
18]. A minority of hospital-based pediatricians [21] and of
general practitioners [22] (GP) in Scotland informed a child’s
GP [21] or the parents [22]. Once parents knew that their chil-
dren were prescribed off-label medicines, parents would ask
for a licensed medicine [18, 19], or they would use the medi-
cine with more caution [19]. The percentage of refusal of off-
label use was higher among parents of otherwise healthy chil-
dren compared with parents of chronically ill children [23].
As summarized in Tables 1 and 3, several national policy
tools indicate that patients should be informed and provide
consent when off-label or unlicensed medicines are pre-
scribed, although it is not always clear to what extent this
consent differs from the regular consent procedure. The
Royal College of Paediatrics and Child Health stated that –
when prescribing off-label medicines to children – it is not
necessary to take additional steps to obtain consent of parents,
caregivers, and children beyond those taken when prescribing
licensed medicines [24]. This is in line with the policy state-
ment issued by the American Academy of Pediatrics in 2014,
which states that administration of off-label medicines in chil-
dren does not warrant special consent if it is based on sound
medical evidence. Obviously, if the off-label use is experi-
mental as part of a study, then the patient (and/or parent)
should be informed of its experimental status and has to pro-
vide the study related assent and/or consent [25]. European
HCPs should know and abide by the appropriate informed
consent laws in their respective countries.
Condition #6 The patient should be monitored for efficacy
and adverse events.
Similar to licensed medications but possibly with a height-
ened vigilance [8], the prescriber and pharmacist should en-
sure appropriate monitoring. Adverse events should be report-
ed to the national pharmacovigilance system byHCPs but also
by the families (parents and or children). In case where med-
icines are prescribed that have reasonable rationale for use but
insufficient evidence to mitigate safety, efficacy, and cost-
effectiveness concerns, yet they are not part of clinical re-
search (“innovate off-label use”), then outcomes should be
evaluated prospectively, documented appropriately, and re-
ported to all stakeholders (HCPs and patients) in a timely
fashion. Regular review should occur to reduce the risk of
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continued use that is not efficacious or is unsafe [28]. In this
way, this condition is true for any prescription, including off-
label or unlicensed use.
Condition #7 The prescriber should consider if off-label
prescribing should be part of a clinical trial.
Finally, in order to increase our knowledge about the effi-
cacy and safety of all medicines used in children, prescribers
should be informed about clinical trials involving off-label
medication in which the patient could participate and inform
the parents and – when applicable – also the children.
Policy statement: recommendations
Off-label and unlicensed prescription practices occur. In order
to facilitate the clinical practice of appropriate, rational and
safe prescribing of off-label medicines to individual children,
the EAP and ESDPPP strongly recommend that:
& All HCPs prescribing medicines to neonates, children, or
adolescents have access to reliable and up-to-date infor-
mation (where possible) on the medicine they prescribe. A
European pediatric formulary with the best evidence on
dosing and safety information could be a useful tool for
improving the rational use of medicines in children and
adolescents [15]. The BNF-c and the Dutch formulary
could serve as templates [16].
& Pediatric clinical pharmacologists/pediatricians/pedi-
atric pharmacists should be actively involved/
consulted in decision-making processes by hospital,
pharmacotherapeutics committees, and national
health-care authorities.
& Enhanced safety monitoring and reporting by parents and
caregivers should be promoted when off-label medicines
are prescribed.
& Parents and patients but also the public should be educated
about off-label and unlicensed use of medicines.
& Where off-label use of a medicine is common and evidence-
based, it should be the shared responsibility of marketing
authorization holder and the relevant regulatory authorities
to take appropriatemeasures to address legal uncertainty and
safety concerns, including updating of the SmPC.
& Health authorities and health insurances should support
and thus reimburse therapeutic practices that are
evidence-based or advocated by a respectable and respon-
sible body of professional opinion, regardless of labelling
status.
& Legislation should be adopted that aims to effectively
stimulate research into off-label medicines, including pub-
lication of clinical trial data [29]), and facilitate the regis-
tration of off-label uses with a positive benefit-harm
balance.
Conclusion
HCPs often have no other option than to prescribe medicines
to children outside the approved conditions for age, therapeu-
tic indication, dose recommendation, formulation, and/or
route of administration. This EAP/ESDPPP policy statement
is intended to offer practical guidance to these HCPs on when
and how to prescribe off-label medicines to children. Several
recommendations should be considered when prescribing off-
label medicines. This list of recommendations may serve as a
checklist for good practice.
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